Pfizer Limited (PFIZER) - Net Assets

Latest as of September 2025: Rs38.48 Billion INR ≈ $416.18 Million USD

Based on the latest financial reports, Pfizer Limited (PFIZER) has net assets worth Rs38.48 Billion INR (≈ $416.18 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs46.06 Billion ≈ $498.07 Million USD) and total liabilities (Rs7.57 Billion ≈ $81.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pfizer Limited liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs38.48 Billion
% of Total Assets	83.56%
Annual Growth Rate	13.42%
5-Year Change	76.24%
10-Year Change	99.12%
Growth Volatility	46.53

Pfizer Limited - Net Assets Trend (2005–2025)

This chart illustrates how Pfizer Limited's net assets have evolved over time, based on quarterly financial data. Also explore PFIZER total assets for the complete picture of this company's asset base.

Annual Net Assets for Pfizer Limited (2005–2025)

The table below shows the annual net assets of Pfizer Limited from 2005 to 2025. For live valuation and market cap data, see Pfizer Limited (PFIZER) market capitalisation.

Year	Net Assets	Change
2025-03-31	Rs42.17 Billion ≈ $456.10 Million	+17.30%
2024-03-31	Rs35.96 Billion ≈ $388.84 Million	+12.10%
2023-03-31	Rs32.07 Billion ≈ $346.86 Million	+11.97%
2022-03-31	Rs28.64 Billion ≈ $309.78 Million	+19.70%
2021-03-31	Rs23.93 Billion ≈ $258.80 Million	-29.52%
2020-03-31	Rs33.95 Billion ≈ $367.21 Million	+12.76%
2019-03-31	Rs30.11 Billion ≈ $325.66 Million	+12.23%
2018-03-31	Rs26.83 Billion ≈ $290.18 Million	+10.93%
2017-03-31	Rs24.19 Billion ≈ $261.59 Million	+14.21%
2016-03-31	Rs21.18 Billion ≈ $229.05 Million	+7.35%
2015-03-31	Rs19.73 Billion ≈ $213.37 Million	+199.66%
2014-03-31	Rs6.58 Billion ≈ $71.20 Million	-61.14%
2013-03-31	Rs16.94 Billion ≈ $183.25 Million	+29.87%
2012-03-31	Rs13.05 Billion ≈ $141.10 Million	+12.14%
2011-03-31	Rs11.63 Billion ≈ $125.82 Million	+17.01%
2010-03-31	Rs9.94 Billion ≈ $107.53 Million	+10.35%
2009-03-31	Rs9.01 Billion ≈ $97.45 Million	+38.69%
2008-03-31	Rs6.50 Billion ≈ $70.26 Million	+47.75%
2007-03-31	Rs4.40 Billion ≈ $47.56 Million	+16.97%
2006-03-31	Rs3.76 Billion ≈ $40.66 Million	+10.73%
2005-03-31	Rs3.40 Billion ≈ $36.72 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Pfizer Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1164.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs24.36 Billion	57.76%
Common Stock	Rs457.50 Million	1.08%
Other Comprehensive Income	Rs4.15 Billion	9.84%
Other Components	Rs13.21 Billion	31.31%
Total Equity	Rs42.17 Billion	100.00%

Pfizer Limited Competitors by Market Cap

The table below lists competitors of Pfizer Limited ranked by their market capitalization.

Company	Market Cap
Tiger Brands Ltd JSE:TBS	$2.33 Billion
BaoJi Titanium Industry Co Ltd SHG:600456	$2.34 Billion
Civitas Resources Inc NYSE:CIVI	$2.34 Billion
Kangwon Land KO:035250	$2.34 Billion
Sendas Distribuidora S.A. SA:ASAI3	$2.33 Billion
Shanghai Beite Technology Co SHG:603009	$2.33 Billion
Lien Hwa Industrial Corp TW:1229	$2.33 Billion
Tokai Carbon Korea Co. Ltd KQ:064760	$2.33 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pfizer Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 35,955,400,000 to 42,174,100,000, a change of 6,218,700,000 (17.3%).
Net income of 7,676,000,000 contributed positively to equity growth.
Dividend payments of 1,602,500,000 reduced retained earnings.
Other comprehensive income increased equity by 1.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs7.68 Billion	+18.2%
Dividends Paid	Rs1.60 Billion	-3.8%
Other Comprehensive Income	Rs1.00	+0.0%
Other Changes	Rs145.20 Million	+0.34%
Total Change	Rs-	17.30%

Book Value vs Market Value Analysis

This analysis compares Pfizer Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 5.11x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 41.40x to 5.11x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-03-31	Rs113.78	Rs4710.60	x
2006-03-31	Rs125.99	Rs4710.60	x
2007-03-31	Rs135.96	Rs4710.60	x
2008-03-31	Rs217.73	Rs4710.60	x
2009-03-31	Rs301.96	Rs4710.60	x
2010-03-31	Rs333.21	Rs4710.60	x
2011-03-31	Rs389.88	Rs4710.60	x
2012-03-31	Rs437.21	Rs4710.60	x
2013-03-31	Rs567.81	Rs4710.60	x
2014-03-31	Rs143.92	Rs4710.60	x
2015-03-31	Rs431.26	Rs4710.60	x
2016-03-31	Rs462.95	Rs4710.60	x
2017-03-31	Rs528.72	Rs4710.60	x
2018-03-31	Rs586.49	Rs4710.60	x
2019-03-31	Rs658.22	Rs4710.60	x
2020-03-31	Rs742.18	Rs4710.60	x
2021-03-31	Rs523.07	Rs4710.60	x
2022-03-31	Rs626.10	Rs4710.60	x
2023-03-31	Rs701.08	Rs4710.60	x
2024-03-31	Rs785.94	Rs4710.60	x
2025-03-31	Rs921.88	Rs4710.60	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pfizer Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 18.20%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 33.65%
• Asset Turnover: 0.46x
• Equity Multiplier: 1.16x
Recent ROE (18.20%) is below the historical average (18.81%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	13.13%	7.52%	1.14x	1.54x	Rs106.34 Million
2006	18.81%	11.23%	1.09x	1.53x	Rs331.37 Million
2007	26.21%	15.35%	1.07x	1.59x	Rs657.62 Million
2008	52.33%	48.71%	0.80x	1.34x	Rs2.75 Billion
2009	33.25%	43.95%	0.62x	1.22x	Rs2.09 Billion
2010	13.77%	17.72%	0.64x	1.21x	Rs374.50 Million
2011	14.52%	19.25%	0.63x	1.19x	Rs525.32 Million
2012	12.99%	15.51%	0.69x	1.21x	Rs389.73 Million
2013	29.70%	53.08%	0.46x	1.22x	Rs3.34 Billion
2014	10.60%	3.77%	2.00x	1.40x	Rs39.78 Million
2015	3.54%	3.77%	0.71x	1.32x	Rs-1.27 Billion
2016	14.40%	15.16%	0.69x	1.38x	Rs931.82 Million
2017	13.92%	17.13%	0.60x	1.35x	Rs948.92 Million
2018	13.42%	18.29%	0.53x	1.38x	Rs917.50 Million
2019	14.25%	20.61%	0.53x	1.31x	Rs1.28 Billion
2020	14.99%	23.66%	0.49x	1.30x	Rs1.70 Billion
2021	20.79%	22.21%	0.69x	1.36x	Rs2.58 Billion
2022	21.39%	23.46%	0.67x	1.36x	Rs3.26 Billion
2023	19.45%	25.73%	0.61x	1.25x	Rs3.03 Billion
2024	15.33%	25.14%	0.52x	1.18x	Rs1.92 Billion
2025	18.20%	33.65%	0.46x	1.16x	Rs3.46 Billion

Industry Comparison

This section compares Pfizer Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

Industry: Drug Manufacturers - General
Average net assets among peers: $5,885,646,182
Average return on equity (ROE) among peers: 24.61%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Pfizer Limited (PFIZER)	Rs38.48 Billion	13.13%	0.20x	$2.33 Billion
GlaxoSmithKline Pharmaceuticals Limited (GLAXO)	$21.40 Billion	20.81%	0.83x	$4.28 Billion
NGL Fine-Chem Limited (NGLFINE)	$328.16 Million	25.38%	1.03x	$147.96 Million
Sanofi India Limited (SANOFI)	$10.14 Billion	15.29%	0.39x	$848.62 Million
SANOFI CONS HEALTHC IND L (SANOFICONR)	$2.73 Billion	66.30%	0.58x	$1.19 Billion
SENORES PHARMACEUTICALS L (SENORES)	$94.96 Million	7.21%	0.53x	$447.85 Million
TTK Healthcare Limited (TTKHLTCARE)	$620.96 Million	12.68%	1.22x	$138.16 Million

About Pfizer Limited

NSE:PFIZER India Drug Manufacturers - General

Market Cap

$2.33 Billion

Rs215.50 Billion INR

Market Cap Rank

#5706 Global

#246 in India

Share Price

Rs4710.60

Change (1 day)

-1.10%

52-Week Range

Rs4243.60 - Rs5889.00

All Time High

Rs6318.30